EE430 Evaluating the Cost Benefit of Fixed-Duration Targeted Therapy in First Line (1ST L) in Chronic Lymphocytic Leukemia (CLL): A Real-World Analysis Using Hungarian Claims Data.

Autor: Jeskó, J¹ (AUTHOR), Hegyi, R² (AUTHOR), Nagy, B¹ (AUTHOR)

Publikováno v: Value in Health. 2024 Supplement, Vol. 27 Issue 12, pS140-S140. 1p.

EE573 Evaluating the Economic Burden of Metastatic Urothelial Carcinoma (mUC): A Real-World Analysis Using Hungarian Claims Data

Autor: Tischler, E, Nagy, B, Macher, T, Jeskó, J, Maráz, AC, Csongvai, C, Kearney, M

Publikováno v: In Value in Health December 2022 25(12) Supplement:S168-S168

1756P Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a nationwide, longitudinal, retrospective study in Hungary

Autor: Maraz, A.C., Nagy, B., Macher, T., Jeskó, J., Tischler, E., Csongvai, C., Kearney, M.

Publikováno v: In Annals of Oncology September 2022 33 Supplement 7:S1341-S1341

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Correction to: Nationwide Study of Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in Hungary.

Autor: Maráz A; Department of Oncotherapy, University of Szeged, Korányi Fasor 12, H-6720, Szeged, Hungary. dr.aniko.maraz@gmail.com., Nagy B; Healthware Consulting Ltd., Budapest, Hungary., Macher T; Healthware Consulting Ltd., Budapest, Hungary., Jeskó J; Healthware Consulting Ltd., Budapest, Hungary., Tischler E; Merck Kft., Budapest, Hungary, an affiliate of Merck KGaA, Darmstadt, Germany., Csongvai C; Merck Kft., Budapest, Hungary, an affiliate of Merck KGaA, Darmstadt, Germany., Kearney M; Global Value Demonstration, Market Access and Pricing (GVAP), the healthcare business of Merck KGaA, Darmstadt, Germany.

Publikováno v: Advances in therapy [Adv Ther] 2024 Feb; Vol. 41 (2), pp. 881-882. Date of Electronic Publication: 2023 Dec 09.